GGS
DGX icon

Galvin Gaustad & Stein’s Quest Diagnostics DGX Stock Holding History

Galvin Gaustad & Stein’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Sell
3,932
-400
-9% -$78.5K 0.06% 149
2026
Q1 		$849K Sell
4,332
-619
-13% -$120K 0.07% 137
2025
Q4 		$859K Sell
4,951
-206
-4% -$37.5K 0.07% 134
2025
Q3 		$983K Sell
5,157
-101
-2% -$17.9K 0.08% 111
2025
Q2 		$944K Sell
5,258
-3,284
-38% -$570K 0.08% 104
2025
Q1 		$1.45M Sell
8,542
-1,243
-13% -$204K 0.13% 83
2024
Q4 		$1.48M Sell
9,785
-197
-2% -$30.6K 0.13% 84
2024
Q3 		$1.55M Sell
9,982
-187
-2% -$27.9K 0.14% 80
2024
Q2 		$1.39M Buy
10,169
+5,890
+138% +$807K 0.13% 78
2024
Q1 		$570K Sell
4,279
-125
-3% -$16.2K 0.05% 117
2023
Q4 		$607K Sell
4,404
-1
-0% -$131 0.06% 108
2023
Q3 		$537K Sell
4,405
-157,625
-97% -$21M 0.05% 112
2023
Q2 		$22.8M Sell
162,030
-3,130
-2% -$431K 2.21% 9
2023
Q1 		$23.4M Sell
165,160
-814
-0.5% -$116K 2.3% 10
2022
Q4 		$26M Sell
165,974
-9,961
-6% -$1.43M 2.61% 5
2022
Q3 		$21.6M Sell
175,935
-475
-0.3% -$62.6K 2.29% 8
2022
Q2 		$23.5M Buy
176,410
+2,907
+2% +$396K 2.38% 5
2022
Q1 		$23.7M Buy
173,503
+9,986
+6% +$1.39M 2.14% 10
2021
Q4 		$28.3M Buy
163,517
+9,467
+6% +$1.44M 2.44% 5
2021
Q3 		$22.4M Buy
154,050
+34,053
+28% +$4.98M 2.16% 11
2021
Q2 		$15.8M Buy
119,997
+3,461
+3% +$453K 1.51% 22
2021
Q1 		$15M Buy
116,536
+2,620
+2% +$323K 1.5% 24
2020
Q4 		$13.6M Buy
+113,916
New +$13.9M 1.43% 30

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Galvin Gaustad & Stein's DGX Position: Q2 2026 in Review

Galvin Gaustad & Stein reduced its Quest Diagnostics (DGX) stake by 9.2% in Q2 2026, selling an estimated $78.5K and leaving 3,932 shares worth $833K. The position accounts for 0.06% of the portfolio, ranked #149.

Galvin Gaustad & Stein first reported a position in DGX in Q4 2020 and has held it in 23 quarters since. The position peaked at $28.3M in Q4 2021. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Galvin Gaustad & Stein held 3,932 shares of Quest Diagnostics worth $833K as of Q2 2026.
  • Galvin Gaustad & Stein sold 400 Quest Diagnostics shares in Q2 2026, an estimated $78.5K.
  • Quest Diagnostics made up 0.06% of Galvin Gaustad & Stein's portfolio in Q2 2026, its #149 holding.
  • Galvin Gaustad & Stein first reported a position in Quest Diagnostics in Q4 2020 and has held it in 23 quarters since.
  • Galvin Gaustad & Stein's Quest Diagnostics position peaked at $28.3M in Q4 2021.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Galvin Gaustad & Stein's 13F filing for Q2 2026, filed 29 Jul 2026.